A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

Timeline

Start

2026-03-18

Primary completion

2026-09-24

Completion

2026-09-24

Drugs

Indications